1 May 2020 Antisense Therapeutics to present at NWR Virtual Health ConferenceAntisense Therapeutics Limited (Antisense or Company) a biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet disease markets is pleased to provide an opportunity for shareholders and investors to join a virtual presentation by Managing Director Mark Diamond, who will present at the NWR Virtual Health Conference on Monday 4 May on the Company’s recent progress in the lead up to upcoming final results from the Phase II clinical trial in Duchenne Muscular Dystrophy. Event: NWR Communications Virtual Health Conference Presenting: Mark Diamond, Antisense Therapeutics Time/date: 11:55am AEST, Monday 4 MayThe event is free and investors can register online to view the presentation here: https://us02web.zoom.us/webinar/register/WN_0FUl8AsyS92f-2BcX-A36A
This announcement was authorised by the Managing Director. For more information please contact: Antisense TherapeuticsMark DiamondManaging Director & CEO +61 (0)3 9827 8999 www.antisense.com.auInvestment EnquiriesGennadi KoutchinXEC Partners [email protected] 1300 932 037 About Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical company, developing and commercialising antisense pharmaceuticals for large unmet markets. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), world leaders in antisense drug development and commercialisation. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). ATL1103 drug designed to block GHr production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly. The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients at the Royal Children’s Hospital, Melbourne.About ATL1102 ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS with the MS animal data having been published in a peer reviewed scientific journal. ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in RR-MS patients. The ATL1102 Phase IIa clinical data has been published in the medical Journal Neurology (Limmroth, V. et al Neurology, 2014; 83(20): 1780-1788).About DMD Duchenne Muscular Dystrophy (DMD) is an X-linked disease that affects 1 in 3600 to 6000 live male births (Bushby et al, 2010). DMD occurs as a result of mutations in the dystrophin gene which causes a substantial reduction in or absence of the dystrophin protein.______________________________________________________________________________________________________6 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 (3) 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AUmuscles and are susceptible to contraction induced injury to muscle that triggers the immune system which exacerbates muscle damage as summarized in a publication co-authored by the Director of the FDA CDERANTISENSE THERAPEUTICS LIMITED ABN 41 095 060 745Page 1Children with DMD have dystrophin deficient For personal use only(Rosenberg et al, 2015). Ongoing deterioration in muscle strength affects lower limbs leading to impaired mobility, and also affects upper limbs, leading to further loss of function and self-care ability. The need for wheelchair use can occur in early teenage years for patients on corticosteroids with a mean age of 13, with respiratory, cardiac, cognitive dysfunction also emerging.With no intervention, the mean age of life is approximately 19 years. The management of the inflammation associated with DMD is currently addressed via the use of corticosteroids, however they are acknowledged as providing insufficient efficacy and are associated with significant side effects. As a consequence, there is an acknowledged high need for newtherapeutic approaches for the treatment of inflammation associated with DMD.Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med 2015, 7: 299rv4.Bushby et al for the DMD Care Consideration Working Group/ Diagnosis and management of Duchenne muscular dystrophy, part 1 Lancet Neurol. 2010 Jan;9(1):77-93 and part 2 Lancet Neurol. 2010 Feb;9(2):177-89.Pinto-Mariz F, Carvalho LR, Araújo AQC, et al. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Skeletal Muscle 2015, 5: 45-55. Patients with a greater number of immune T cells expressing high levels of CD49d have more severe and progressive disease and are wheelchair bound by the age of 10 despite being on corticosteroid treatment (Pinto Mariz et al, 2015). ______________________________________________________________________________________________________6 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA TEL . +61 (3) 9827 8999 FAX +61 3 9859 7701 WEB WWW.ANTISENSE.COM.AUANTISENSE THERAPEUTICS LIMITED ABN 41 095 060 745Page 2For personal use only
(20min delay)
